The European lead factory—an experiment in collaborative drug discovery
Journal Title: Journal of Medicines Development Sciences - Year 2015, Vol 1, Issue 1
Abstract
The European Lead Factory (ELF) is a unique collaborative public–private partnership aiming to deliver innovative drug discovery starting points and improving the value generated by ultra-High Throughput Screening (uHTS) approaches. Composed of a unique compound collection derived from private pharmaceutical company collections and complemented with new chemistries from a unique public collection, it offers a unique uHTS platform accessible to both private companies and publicly funded researchers. One of the key challenges in setting up ELF has been to balance access to screening results with protecting the value of compounds in the collection. Through an ‘honest data broker’ data management platform and a royalty reward scheme based on achieved milestones, ELF has been able to overcome these challenges. Set up in 2013, it has already accepted 42 targets for screening, submitted by publicly funded researchers, and generated 12 Qualified Hit Lists. In addition, 55,000 new library compounds have been generated by the public partners and added to the 320,000 compounds made available by the companies. Although it faced many challenges in becoming operational, this unique experiment in collaboration is already generating exciting results that will hopefully, eventually lead to better medicines and tools to advance our biological knowledge, and should act as a template for future approaches in the area.
Authors and Affiliations
Hugh Laverty, Kristina Maria Orrling, Fabrizio Giordanetto, Magali Poinot, Eckhard Ottow,Ton Wilhelmus Rijnders, Dimitrios Tzalis and Stefan Jaroch
Keywords
Related Articles
- EP ID EP679257
- DOI -
- Views 172
- Downloads 0
New initiatives for transforming clinical research in Korea
Korea has continuously sought to improve its regulatory environment for clinical trials and has invested heavily in clinical trial infrastructure and technology since the early 2000’s. A strategic investment through the...
It pays to promote joint PhD programmes between academia and the private sector
The prosperity of a country is closely related to its level of education to fuel research and innovation. Doctoral graduates have attained the highest education level and should be the key players in research and innovat...
Investigative safety strategies to improve success in drug development
Understanding and reducing attrition rate remains a key challenge in drug development. Preclinical and clinical safety issues still represent about 40% of drug discontinuation, of which cardiac and liver toxicities are t...
Japanese initiative for education in pharmaceutical medicine and clinical research training
Development of new medicines has become increasingly difficult with less possibility of success in seeds-finding and ever rising operational costs. Failure to comply with ethical standards for human research protection a...
The Faculty of Pharmaceutical Medicine – Foundation, function and future
The Faculty of Pharmaceutical Medicine was established in the United Kingdom (UK) in 1989 to develop and maintain competence, ethics and the highest professional standards of practice in the discipline. This article char...